SG10201902903RA - Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine - Google Patents

Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine

Info

Publication number
SG10201902903RA
SG10201902903RA SG10201902903RA SG10201902903RA SG10201902903RA SG 10201902903R A SG10201902903R A SG 10201902903RA SG 10201902903R A SG10201902903R A SG 10201902903RA SG 10201902903R A SG10201902903R A SG 10201902903RA SG 10201902903R A SG10201902903R A SG 10201902903RA
Authority
SG
Singapore
Prior art keywords
ylvinyl
pyrrolidin
pyrimidine
synthesis
salt forms
Prior art date
Application number
SG10201902903RA
Other languages
English (en)
Inventor
Srinivisa Rao Akireddy
Balwinder Bhatti
Timothy Cuthbertson
Gary Dull
Craig Miller
Mitchener, Jr
Julio Munoz
Pieter Otten
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41650077&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201902903R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of SG10201902903RA publication Critical patent/SG10201902903RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201902903RA 2008-12-01 2009-11-30 Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine SG10201902903RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11879608P 2008-12-01 2008-12-01

Publications (1)

Publication Number Publication Date
SG10201902903RA true SG10201902903RA (en) 2019-05-30

Family

ID=41650077

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201902903RA SG10201902903RA (en) 2008-12-01 2009-11-30 Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
SG10201406410UA SG10201406410UA (en) 2008-12-01 2009-11-30 Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201406410UA SG10201406410UA (en) 2008-12-01 2009-11-30 Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine

Country Status (26)

Country Link
US (1) US8604191B2 (fr)
EP (2) EP2364307B1 (fr)
JP (1) JP5710490B2 (fr)
KR (1) KR20110098763A (fr)
CN (1) CN102232070A (fr)
AU (1) AU2009322624B2 (fr)
BR (1) BRPI0922759A2 (fr)
CA (2) CA3090738C (fr)
CL (1) CL2011001258A1 (fr)
CO (1) CO6390106A2 (fr)
DK (1) DK3279195T3 (fr)
EC (1) ECSP11011167A (fr)
ES (2) ES2641762T3 (fr)
HK (1) HK1250572A1 (fr)
HU (1) HUE050540T2 (fr)
IL (2) IL266097B (fr)
MX (1) MX2011005611A (fr)
NZ (3) NZ592554A (fr)
PE (1) PE20110589A1 (fr)
PL (1) PL3279195T3 (fr)
PT (1) PT3279195T (fr)
RU (2) RU2533819C2 (fr)
SG (2) SG10201902903RA (fr)
UA (1) UA107336C2 (fr)
WO (1) WO2010065443A1 (fr)
ZA (1) ZA201103737B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
WO2011112428A2 (fr) * 2010-03-11 2011-09-15 Targacept, Inc. Composés arylvinylazacycloalcane pour la constipation
EP3848028B1 (fr) 2014-10-20 2024-05-29 Oyster Point Pharma, Inc. Méthodes de traitement de troubles oculaires
KR102512777B1 (ko) * 2016-04-07 2023-03-23 오이스터 포인트 파마 인코포레이티드 안구 장애의 치료 방법
TW202019417A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合
WO2020014217A1 (fr) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Méthodes de traitement d'états oculaires
WO2021222230A1 (fr) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Administration locale d'agonistes du récepteur nicotinique de l'acétylcholine pour l'inhibition d'infections à coronavirus

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649041A (en) * 1983-07-20 1987-03-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
SU1605922A3 (ru) * 1987-05-01 1990-11-07 Фудзисава Фармасьютикал Ко., Лтд (Фирма) Способ получени производных пирролидина или их солей
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
ES2097703B1 (es) * 1995-04-12 1997-12-01 Decox S L Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
AU780492B2 (en) * 1999-11-01 2005-03-24 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6846835B2 (en) * 2000-07-11 2005-01-25 Banyu Pharmaceutical Co., Ltd. Ester derivatives
WO2003013526A1 (fr) * 2001-08-08 2003-02-20 Merck & Co. Inc. Composes anticoagulants
US6872827B2 (en) * 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
CN101022728B (zh) * 2004-03-25 2012-08-08 詹森药业有限公司 咪唑化合物
AR053364A1 (es) * 2005-04-20 2007-05-02 Smithkline Beecham Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
WO2008157365A2 (fr) * 2007-06-15 2008-12-24 Targacept, Inc. Procédés ou utilisations et compositions pour traiter ou empêcher la douleur neuropathique
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine

Also Published As

Publication number Publication date
ES2820857T3 (es) 2021-04-22
BRPI0922759A2 (pt) 2016-01-05
KR20110098763A (ko) 2011-09-01
EP3279195B1 (fr) 2020-07-01
IL266097A (en) 2019-06-30
JP2012510471A (ja) 2012-05-10
NZ703381A (en) 2016-03-31
RU2014136983A (ru) 2016-04-10
US20110281895A1 (en) 2011-11-17
IL212798A0 (en) 2011-07-31
AU2009322624A1 (en) 2010-06-10
CA3090738A1 (fr) 2010-06-10
RU2533819C2 (ru) 2014-11-20
UA107336C2 (ru) 2014-12-25
CN102232070A (zh) 2011-11-02
IL266097B (en) 2022-07-01
ES2641762T3 (es) 2017-11-13
PL3279195T3 (pl) 2020-12-14
EP3279195A1 (fr) 2018-02-07
DK3279195T3 (en) 2020-08-17
AU2009322624B2 (en) 2015-06-11
ZA201103737B (en) 2012-01-25
SG10201406410UA (en) 2014-11-27
ECSP11011167A (es) 2011-10-31
MX2011005611A (es) 2011-09-15
RU2011127010A (ru) 2013-01-10
CA3090738C (fr) 2023-06-13
CA2742366A1 (fr) 2010-06-10
PE20110589A1 (es) 2011-09-07
PT3279195T (pt) 2020-09-29
IL212798B (en) 2019-05-30
NZ592554A (en) 2013-08-30
JP5710490B2 (ja) 2015-04-30
EP2364307A1 (fr) 2011-09-14
HK1250572A1 (zh) 2018-12-28
EP2364307B1 (fr) 2017-07-05
RU2700796C2 (ru) 2019-09-23
US8604191B2 (en) 2013-12-10
CL2011001258A1 (es) 2011-09-02
CO6390106A2 (es) 2012-02-29
NZ611965A (en) 2015-01-30
CA2742366C (fr) 2020-09-22
HUE050540T2 (hu) 2020-12-28
WO2010065443A1 (fr) 2010-06-10

Similar Documents

Publication Publication Date Title
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
RS54408B1 (en) SODIUM SO 6-FLUOR-3-HYDROXY-2-PYRAZINE CARBOXAMIDE
SG10201902903RA (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
MX2010002902A (es) Pirimidinas anti-infecciosas y usos de las mismas.
MX2011010332A (es) Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
MX2010008040A (es) Derivados de pirimidina 5-fluoro como fungicidas.
MX340064B (es) Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos.
PL2126020T3 (pl) Hydrofobowo modyfikowane polialkilenoiminy jako inhibitory przenoszenia barwnika
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
HK1115500A1 (en) Isoquinolines as igf-1r inhibitors
MX2010001938A (es) Metodos para preparar compuestos basados en 4-fenil-6-(2,2,2-trifl uoro-1-feniletoxi)pirimidina.
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
TN2011000355A1 (en) Novel microbiocides
TN2010000585A1 (en) Pharmaceutical compositions of rosuvastatin calcium
MX2009000198A (es) Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo.
TN2012000034A1 (en) Methylpyrrolopyrimidinecarboxamides
DE602008002598D1 (en) Cyclohexylderivate
IN2012DN01223A (fr)
MD4009B1 (en) Use of 1-methyl-4-(N-methylaminobutyl-4)- Beta -carboline as antituberculous remedy
EA201170072A1 (ru) Способ асимметричного синтеза замещенных 2-аминотиазолонов
UA87364C2 (ru) ДИКАЛИЙНАЯ СОЛЬ N-(9-ФЛУОРЕНИЛИДЕН)-ГИДРАЗИДА о-ОКСИБЕНЗОАТНОЙ КИСЛОТЫ, КОТОРАЯ ПРОЯВЛЯЕТ ПРОТИВОТУБЕРКУЛЕЗНОЕ ДЕЙСТВИЕ
UA87255C2 (en) Use of n-(2-(morpholine-4-yl)propyl)-2-naphthalimidoacetamide as interferone-inducing antiviral agent
UA87367C2 (ru) ДИНАТРИЕВАЯ СОЛЬ N-(9-ФЛУОРЕНИЛИДЕН)-ГИДРАЗИДА о-ОКСИБЕНЗОАТНОЙ КИСЛОТЫ, КОТОРАЯ ПРОЯВЛЯЕТ ПРОТИВОТУБЕРКУЛЕЗНОЕ ДЕЙСТВИЕ
UA87793C2 (ru) 3-амино-1,1,1-трифторопропан-2-сульфонат натрия